These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 22797359)
1. Fibrinolytic proteins in human bile accelerate lysis of plasma clots and induce breakdown of fibrin sealants. Boonstra EA; Adelmeijer J; Verkade HJ; de Boer MT; Porte RJ; Lisman T Ann Surg; 2012 Aug; 256(2):306-12. PubMed ID: 22797359 [TBL] [Abstract][Full Text] [Related]
3. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro. Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448 [TBL] [Abstract][Full Text] [Related]
4. Role of fibrin sealants in liver surgery. de Boer MT; Boonstra EA; Lisman T; Porte RJ Dig Surg; 2012; 29(1):54-61. PubMed ID: 22441621 [TBL] [Abstract][Full Text] [Related]
5. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators. Sabovic M; Lijnen HR; Keber D; Collen D Thromb Haemost; 1989 Dec; 62(4):1083-7. PubMed ID: 2515603 [TBL] [Abstract][Full Text] [Related]
6. MASP-1 of the complement system alters fibrinolytic behaviour of blood clots. Jenny L; Noser D; Larsen JB; Dobó J; Gál P; Pál G; Schroeder V Mol Immunol; 2019 Oct; 114():1-9. PubMed ID: 31325724 [TBL] [Abstract][Full Text] [Related]
7. Clot lysis mediated by cultured human microvascular endothelial cells. Speiser W; Anders E; Binder BR; Müller-Berghaus G Thromb Haemost; 1988 Dec; 60(3):463-7. PubMed ID: 3149047 [TBL] [Abstract][Full Text] [Related]
8. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model. Guimarães AH; Rijken DC Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222 [TBL] [Abstract][Full Text] [Related]
9. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters. Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650 [TBL] [Abstract][Full Text] [Related]
10. An experimental and theoretical study on the dissolution of mural fibrin clots by tissue-type plasminogen activator. Wootton DM; Popel AS; Alevriadou BR Biotechnol Bioeng; 2002 Feb; 77(4):405-19. PubMed ID: 11787013 [TBL] [Abstract][Full Text] [Related]
11. Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential. Onundarson PT; Francis CW; Marder VJ J Lab Clin Med; 1992 Jul; 120(1):120-8. PubMed ID: 1613318 [TBL] [Abstract][Full Text] [Related]
12. Increased plasma clot permeability and susceptibility to lysis are associated with heavy menstrual bleeding of unknown cause: a case-control study. Szczepaniak P; Zabczyk M; Undas A PLoS One; 2015; 10(4):e0125069. PubMed ID: 25909989 [TBL] [Abstract][Full Text] [Related]
14. Fibrin clot lysis by tissue plasminogen activator (tPA) is impaired in plasma from pediatric patients undergoing orthotopic liver transplantation. Leaker MT; Brooker LA; Mitchell LG; Weitz JI; Superina R; Andrew ME Transplantation; 1995 Jul; 60(2):144-7. PubMed ID: 7624956 [TBL] [Abstract][Full Text] [Related]
15. A reconstituted dilute blood clot lysis assay for the medium throughput screening of thrombolytic compounds. Gadbut AP; Schullek JR; Hanel AM; MacAllan DR Anal Biochem; 1999 May; 270(1):24-32. PubMed ID: 10328761 [TBL] [Abstract][Full Text] [Related]
16. Influence of homocysteine on fibrin network lysis. Lauricella AM; Quintana I; Castañon M; Sassetti B; Kordich L Blood Coagul Fibrinolysis; 2006 Apr; 17(3):181-6. PubMed ID: 16575255 [TBL] [Abstract][Full Text] [Related]
17. Human thrombin and calcium bound factor Xa significantly shorten tPA-induced fibrin clot lysis time via neutralization of plasminogen activator inhibitor type 1 activity. Urano T; Nagai N; Matsuura M; Ihara H; Takada Y; Takada A Thromb Haemost; 1998 Jul; 80(1):161-6. PubMed ID: 9684803 [TBL] [Abstract][Full Text] [Related]
18. Biochemical and biophysical conditions for blood clot lysis. Sabovic M; Blinc A Pflugers Arch; 2000; 440(5 Suppl):R134-6. PubMed ID: 11005642 [TBL] [Abstract][Full Text] [Related]
19. The effect of flow on lysis of plasma clots in a plasma environment. Sakharov DV; Rijken DC Thromb Haemost; 2000 Mar; 83(3):469-74. PubMed ID: 10744155 [TBL] [Abstract][Full Text] [Related]
20. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]